What are the recommended first-line treatment options for managing Adult-Onset Still's Disease in adults?

Recommended first-line treatment options for managing adult-onset Still's disease in adults are not explicitly detailed in the provided UK guideline excerpts.

However, adult-onset Still's disease is an inflammatory condition often managed similarly to other systemic inflammatory arthritis conditions. First-line treatment typically involves non-steroidal anti-inflammatory drugs (NSAIDs) to control symptoms and inflammation.

Glucocorticoids (oral or intramuscular) are commonly used as short-term bridging therapy to rapidly reduce inflammation while waiting for disease-modifying anti-rheumatic drugs (DMARDs) to take effect.

Conventional DMARDs such as methotrexate are often introduced early to control disease activity and prevent progression, especially if symptoms are persistent or severe.

Biological DMARDs may be considered if there is inadequate response to conventional DMARDs and glucocorticoids.

These treatment principles align with management strategies for systemic inflammatory arthritis conditions like rheumatoid arthritis and spondyloarthritis, as per NICE guidelines.